We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Closure System Permanently Seals Varicose Veins

By HospiMedica International staff writers
Posted on 01 Mar 2015
Image: The VenaSeal Closure System (Photo courtesy of Sapheon).
Image: The VenaSeal Closure System (Photo courtesy of Sapheon).
A novel embolic system uses an adhesive agent that polymerizes inside superficial varicose veins of the legs, sealing them shut.

The VenaSeal Closure System is composed of a specially formulated adhesive (n-butyl-2-cyanoacrylate) and a delivery system that includes a catheter, guidewire, dispenser gun, dispenser tips, and syringes. The VenaSeal Closure System does not require tumescent anesthesia to be injected peripherally into the leg, and because there are no pre-procedures drugs involved, patients can usually return to their normal activities right after the treatment, with just a Band-Aid in place.

For example, to seal the great saphenous vein (GSV), the catheter is first guided via ultrasound (US) towards the saphenofemoral junction (SFJ); once properly placed near the SFJ, the adhesive is injected into the lumen, sealing the vein. The procedure is then repeated every three cm along the GSV. Once closed, blood is immediately rerouted through other healthy veins in the leg. The VenaSeal Closure system is a product of Sapheon (Morrisville, NC, USA), a part of Covidien (Dublin, Ireland), and has been approved by the US Food and Drug Administration (FDA).

“Cyanoacrylate embolization is an effective and durable solution to the problem of incompetent great saphenous veins; long-term effectiveness is high,” said Prof. Thomas Proebstle, MD, of Mainz University (Germany), who led the European multicenter clinical study of the system. “The elimination of the need for perivenous tumescent anesthesia and post-interventional compression stockings, along with the associated side effects, results in significantly improved treatment.”

“This new system is the first to permanently treat varicose veins by sealing them with an adhesive, thereby giving patients another treatment option for this common condition,” said William Maisel, MD, MPH, acting director of the office of device evaluation in the FDA’s Center for Devices and Radiological Health (CDRH). “Because the VenaSeal system does not incorporate heat application or cutting, the in-office procedure can allow patients to quickly return to their normal activities, with less bruising.”

Varicose veins (also known as venous reflux disease) occur when valves inside the veins break and blood is unable to circulate properly. This is a common condition that affects both men (25%) and women (40%). Varicose veins can occur anywhere from the groin to the ankle.

Related Links:

Sapheon
Covidien


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Hemostatic Agent
HEMOBLAST Bellows
New
Measuring Rod
seca 233

Channels

Critical Care

view channel
The intelligent wound dressing consists of a granular hydrogel (Photo courtesy of Apoorv Singh/ETH Zurich)

Intelligent Wound Dressing Reduces Inflammation and Promotes Healing

Chronic wounds, especially those caused by diabetes or circulatory disorders, are a widespread medical problem that burden healthcare systems. Patients often suffer from open skin lesions that fail to... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more